Diamyd Medical AB (publ) (DMYD-B.ST)
SEK 16.12
(2.54%)
SEK 16.12
(2.54%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 | 30.67 Million SEK | 93.33% |
| 2023 | 15.86 Million SEK | 0.0% |
| 2022 | - SEK | 0.0% |
| 2021 | - SEK | 0.0% |
| 2020 | - SEK | 0.0% |
| 2019 | - SEK | 0.0% |
| 2018 | - SEK | 0.0% |
| 2017 | - SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| 2013 | - SEK | 0.0% |
| 2012 | - SEK | 0.0% |
| 2011 | - SEK | 0.0% |
| 2010 | - SEK | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 31.57 Million SEK | 30.75% |
| 2024 Q4 | 30.67 Million SEK | -2.85% |
| 2024 Q1 | 24.14 Million SEK | 52.21% |
| 2024 Q2 | 24.14 Million SEK | 0.0% |
| 2023 Q1 | - SEK | 0.0% |
| 2023 Q4 | 15.86 Million SEK | 0.0% |
| 2023 Q3 | - SEK | 0.0% |
| 2023 FY | 15.86 Million SEK | 0.0% |
| 2023 Q2 | - SEK | 0.0% |
| 2022 Q2 | - SEK | 0.0% |
| 2022 Q4 | - SEK | 0.0% |
| 2022 Q1 | - SEK | 0.0% |
| 2022 FY | - SEK | 0.0% |
| 2022 Q3 | - SEK | 0.0% |
| 2021 Q3 | - SEK | 0.0% |
| 2021 Q2 | - SEK | 0.0% |
| 2021 Q4 | - SEK | 0.0% |
| 2021 Q1 | - SEK | 0.0% |
| 2021 FY | - SEK | 0.0% |
| 2020 Q1 | - SEK | 0.0% |
| 2020 FY | - SEK | 0.0% |
| 2020 Q2 | - SEK | 0.0% |
| 2020 Q3 | - SEK | 0.0% |
| 2020 Q4 | - SEK | 0.0% |
| 2019 Q2 | - SEK | 0.0% |
| 2019 FY | - SEK | 0.0% |
| 2019 Q4 | - SEK | 0.0% |
| 2019 Q3 | - SEK | 0.0% |
| 2019 Q1 | - SEK | 0.0% |
| 2018 Q2 | - SEK | 0.0% |
| 2018 Q4 | - SEK | 0.0% |
| 2018 Q3 | - SEK | 0.0% |
| 2018 Q1 | - SEK | 0.0% |
| 2018 FY | - SEK | 0.0% |
| 2017 Q3 | - SEK | 0.0% |
| 2017 Q2 | - SEK | 0.0% |
| 2017 Q4 | - SEK | 0.0% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q1 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2015 Q3 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 Q2 | - SEK | 0.0% |
| 2014 Q2 | - SEK | 0.0% |
| 2014 Q1 | - SEK | 0.0% |
| 2014 Q4 | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| 2014 Q3 | - SEK | 0.0% |
| 2013 Q3 | - SEK | 0.0% |
| 2013 Q4 | - SEK | 0.0% |
| 2013 FY | - SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2012 Q1 | - SEK | 0.0% |
| 2012 FY | - SEK | 0.0% |
| 2012 Q3 | - SEK | 0.0% |
| 2012 Q2 | - SEK | 0.0% |
| 2012 Q4 | - SEK | 0.0% |
| 2011 Q2 | - SEK | 0.0% |
| 2011 FY | - SEK | 0.0% |
| 2011 Q3 | - SEK | 0.0% |
| 2011 Q4 | - SEK | 0.0% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q4 | - SEK | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 16.09 Million SEK | -90.545% |
| Ziccum AB (publ) | 857 Thousand SEK | -3478.996% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 4.97 Million SEK | -516.027% |
| Sprint Bioscience AB (publ) | - SEK | -Infinity% |
| Mendus AB (publ) | 24.48 Million SEK | -25.253% |
| Genovis AB (publ.) | 79.32 Million SEK | 61.331% |
| Intervacc AB (publ) | 181 Thousand SEK | -16845.856% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.61 Million SEK | -48.814% |
| Active Biotech AB (publ) | 3 Million SEK | -922.4% |
| Magle Chemoswed Holding AB (publ) | 60.3 Million SEK | 49.136% |
| Bio-Works Technologies AB (publ) | - SEK | -Infinity% |
| Aptahem AB (publ) | 5 Million SEK | -513.44% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | - SEK | -Infinity% |
| Infant Bacterial Therapeutics AB (publ) | - SEK | -Infinity% |
| Fluicell AB (publ) | - SEK | -Infinity% |
| Saniona AB (publ) | 71.4 Million SEK | 57.047% |
| Lipigon Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Biovica International AB (publ) | 7.82 Million SEK | -291.824% |
| Spago Nanomedical AB (publ) | - SEK | -Infinity% |
| AcouSort AB (publ) | - SEK | -Infinity% |
| Xintela AB (publ) | - SEK | -Infinity% |
| Abliva AB (publ) | 424 Thousand SEK | -7133.962% |
| Egetis Therapeutics AB (publ) | 108.6 Million SEK | 71.757% |
| Karolinska Development AB (publ) | 3.07 Million SEK | -899.088% |
| OncoZenge AB (publ) | - SEK | -Infinity% |
| Amniotics AB (publ) | 2.58 Million SEK | -1088.837% |
| 2cureX AB (publ) | - SEK | -Infinity% |
| CombiGene AB (publ) | - SEK | -Infinity% |
| Asarina Pharma AB (publ) | 1 Million SEK | -2967.2% |
| Calliditas Therapeutics AB (publ) | 979.13 Million SEK | 96.867% |
| Camurus AB (publ) | 24.5 Million SEK | -25.156% |
| Corline Biomedical AB | - SEK | -Infinity% |
| IRLAB Therapeutics AB (publ) | 27.56 Million SEK | -11.268% |
| Isofol Medical AB (publ) | - SEK | -Infinity% |
| I-Tech AB | - SEK | -Infinity% |
| Hansa Biopharma AB (publ) | 866.76 Million SEK | 96.461% |
| Cyxone AB (publ) | 858 Thousand SEK | -3474.825% |
| ExpreS2ion Biotech Holding AB (publ) | 1.71 Million SEK | -1692.636% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | - SEK | -Infinity% |
| Xspray Pharma AB (publ) | 36.8 Million SEK | 16.67% |
| Elicera Therapeutics AB (publ) | - SEK | -Infinity% |
| Nanologica AB (publ) | 666 Thousand SEK | -4505.405% |
| SynAct Pharma AB | 637 Thousand SEK | -4715.071% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | 850 Thousand SEK | -3508.471% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 1.76 Million SEK | -1641.738% |
| BioInvent International AB (publ) | 23.24 Million SEK | -31.957% |
| Alzinova AB (publ) | 800 Thousand SEK | -3734.0% |
| Oncopeptides AB (publ) | 106.48 Million SEK | 71.196% |
| Pila Pharma AB (publ) | 773.08 Thousand SEK | -3867.507% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | - SEK | -Infinity% |
| Simris Alg AB (publ) | 90.74 Million SEK | 66.198% |
| Xbrane Biopharma AB (publ) | 231.47 Million SEK | 86.75% |
| Ascelia Pharma AB (publ) | 1.06 Million SEK | -2790.858% |
| Diagonal Bio AB (publ) | - SEK | -Infinity% |